It is expected that pharmacogenomics is most likely cost - effective, since it reduces
the incidence of adverse drug reactions, which can reciprocally reduce healthcare expenditure at the national level.
They opted for higher doses
of pramlintide (240 ug TID [three times per day]-RRB- because in dose - escalation studies, the
incidence and severity
of adverse drug reactions was consistently low at all doses tested.